Article paru dans Tribune’k Hemostase D’après la communication orale de M. Jandrot-Perrus et al., abstract OC 06.1, 27th Congress of ISTH – International Society on Thrombosis and Haemostasis 2019. Dr Caroline VAYNE, CHRU de Tours Extrait La glycoprotéine GPVI est principalement impliquée dans l’activation plaquettaire en conditions pathologiques et représente donc une cible potentielle pour le […]
April 2019. The first study to test an experimental antiplatelet compound in humans found the therapy inhibited clot formation without increasing bleeding, suggesting it could avoid that dangerous side effect of other clot-preventing drugs.
April 2019. An experimental antiplatelet compound inhibited clot formation without increasing bleeding, a common and potentially dangerous side effect of current anticlotting therapies, according to new phase I research in Arteriosclerosis, Thrombosis
April 2019. An experimental type of anti-clotting drug appears to be safe, according to an early-phase study.
April 2019. A new blood thinner may help prevent stroke, but without the risk for excessive bleeding, according to the results of an early trial.
April 2019. Widely prescribed blood thinners such as COX-1 inhibitor aspirin and P2Y12 antagonist Plavix have a common problem: By decreasing platelet aggregation, they also increase the risk of uncontrolled bleeding.